Barinthus Biotherapeutics plc American Depositary Shares
Compare this stock
BRNS Stock Report Card
$
61%
Performance
Score:
10/100
BRNS returned -42.40% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Earnings
Score:
100/100
BRNS has missed earnings 1 times in the last 20 quarters.
Volatility
Score:
50/100
BRNS has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.
Barinthus Biotherapeutics plc American Depositary Shares Summary
Nasdaq / BRNS
Healthcare
Biotechnology
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
BRNS scored highly on our reportcard. Here are some similar companies and how they performed.
